Sanofi-aventis Enters into Research Collaboration with Audion Therapeutics to Develop Potential Treatments for Hearing Loss
Audion Therapeutics announced that it has entered into a two-year agreement with Sanofi to to develop potential treatments for hearing loss through the optimization of small molecules by using a regenerative medicine approach.
This collaborative research will utilize technology developed at the Massachusetts Eye and Ear Infirmary in the Eaton-Peabody Laboratory by investigator and Audion co-founder Dr. Albert Edge, who has strong expertise in stem cells and inner ear biology. Audion licensed Dr. Edge's technology from Mass Eye and Ear. Under the terms of the agreement, Sanofi has an option to license technology rights from Audion related to research conducted under the collaboration.
"This alliance with Sanofi validates our thinking around developing small molecule regenerative drugs for the treatment of hearing loss. We are very excited about this collaboration," said RolfJan Rutten and Helmuth van Es, founders of Audion Therapeutics. "Sanofi's interest in the hearing loss field plus its vast experience and infrastructure in small-molecule drug discovery make them the perfect partner to move this program forward as diligently as possible."
Other news from the department business & finance
